Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VGN017
MIFTS: 47

Vaginal Cancer

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vaginal Cancer

About this section

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer 12 54 44 15
Vaginal Neoplasms 45 74
Vaginal Malignant Epithelial Tumor 60
Malignant Neoplasm of Vagina 12
Malignant Vaginal Neoplasm 74
Malignant Tumor of Vagina 12
Malignant Vaginal Tumor 12
Neoplasm of Vagina 12
Vaginal Carcinoma 60
Vaginal Neoplasia 74
Vaginal Neoplasm 17
Vagina Carcinoma 74
Vagina Neoplasm 12
Vaginal Tumor 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:119
ICD9CM 36 184.0
MeSH 45 D014625
NCIt 51 C3437 C7410
ICD10 34 C52
ICD10 via Orphanet 35 C52
UMLS via Orphanet 75 C0262659
Orphanet 60 ORPHA180247
Sources

Summaries for Vaginal Cancer

About this section
MedlinePlus : 44 Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Vaginal Cancer, also known as vaginal neoplasms, is related to vaginal carcinosarcoma and vaginal disease, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways is Antigen Presentation- Folding, assembly and peptide loading of class I MHC. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include testes, cervix and uterus, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A female reproductive system cancer that is located in the vagina.

Wikipedia : 77 Vaginal cancer is a malignant tumor that forms in the tissues of the vagina. Primary tumors are most... more...

Sources

Related Diseases for Vaginal Cancer

About this section

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 vaginal carcinosarcoma 11.1
2 vaginal disease 11.0
3 vaginal glandular tumor 11.0
4 vaginal squamous tumor 11.0
5 vagina sarcoma 11.0
6 vaginal yolk sac tumor 11.0
7 vaginal endometrial stromal tumor 11.0
8 malignant germ cell tumor of the vagina 10.2
9 vulvovaginal rhabdomyosarcoma 10.2
10 chylomicron retention disease 10.0 SAR1B SLC10A2
11 cervix disease 9.9 MAPK8IP1 SMUG1
12 uterine anomalies 9.9 MAPK8IP1 SMUG1
13 female reproductive system disease 9.9 MAPK8IP1 SMUG1
14 intrahepatic cholestasis of pregnancy 9.9 HLA-G SLC10A2
15 squamous cell carcinoma 9.9
16 cervical intraepithelial neoplasia 9.9
17 vulvar intraepithelial neoplasia 9.9
18 leukemia 9.9
19 papilloma 9.9
20 reproductive system disease 9.8 MAPK8IP1 SMUG1
21 mayer-rokitansky-kuster-hauser syndrome 9.7
22 graft-versus-host disease 9.7
23 sclerosing cholangitis, neonatal 9.7
24 thrombosis 9.7
25 endometrial hyperplasia 9.7
26 hydronephrosis 9.7
27 in situ carcinoma 9.7
28 chronic graft versus host disease 9.7
29 retinoblastoma 9.7
30 leukemia, acute myeloid 9.7
31 cervical cancer 9.7
32 endometrial cancer 9.7
33 polyarteritis nodosa, childhood-onset 9.7
34 squamous cell papilloma 9.7
35 t-cell leukemia 9.7
36 myeloid leukemia 9.7
37 polyarteritis nodosa 9.7
38 polymyositis 9.7
39 hemangiopericytoma, malignant 9.7
40 gastrointestinal stromal tumor 9.7
41 choriocarcinoma 9.7

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Cervical Cancer
Deficiency Anemia Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:



Diseases related to Vaginal Cancer
Sources

Symptoms & Phenotypes for Vaginal Cancer

About this section

UMLS symptoms related to Vaginal Cancer:


pelvic pain, vaginal pruritus

GenomeRNAi Phenotypes related to Vaginal Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.32 MAPK8IP1 MYLK2
2 Decreased viability GR00221-A-1 9.32 MYLK2
3 Decreased viability GR00221-A-2 9.32 MYLK2
4 Decreased viability GR00221-A-4 9.32 MAPK8IP1 MYLK2
5 Decreased viability GR00301-A 9.32 MAPK8IP1
6 Decreased viability GR00342-S-3 9.32 MAPK8IP1
7 Decreased viability GR00402-S-2 9.32 MAPK8IP1 MYLK2

MGI Mouse Phenotypes related to Vaginal Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.1 HLA-G HPD MAPK8IP1 SAR1B SLC10A2 SMUG1
Sources

Drugs & Therapeutics for Vaginal Cancer

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
4
Ondansetron Approved Phase 3 99614-02-5 4595
5
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
6
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
7 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
8 Cola Phase 3,Phase 2,Phase 1
9 Liver Extracts Phase 3,Phase 2,Phase 1
10 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
11 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
12 Antineoplastic Agents, Hormonal Phase 3
13 Gastrointestinal Agents Phase 3,Phase 1
14 Anesthetics Phase 3
15 Anesthetics, Intravenous Phase 3
16 Narcotics Phase 3
17 Central Nervous System Depressants Phase 3,Phase 2
18 Peripheral Nervous System Agents Phase 3,Phase 2
19 Analgesics, Opioid Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Analgesics Phase 3,Phase 2
22 Anesthetics, General Phase 3
23 DHEA (Dehydroepiandrosterone) Phase 3
24 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
25 Dermatologic Agents Phase 3,Phase 2
26 Neurotransmitter Agents Phase 3,Phase 2
27 Psychotropic Drugs Phase 3,Phase 2
28 Tranquilizing Agents Phase 3,Phase 2
29 Serotonin Agents Phase 3
30 Serotonin Antagonists Phase 3
31 Autonomic Agents Phase 3
32 Emetics Phase 3
33 Anti-Anxiety Agents Phase 3
34 Antipsychotic Agents Phase 3
35 Antiemetics Phase 3
36 Antipruritics Phase 3
37
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
38
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
39
Indinavir Approved Phase 2 150378-17-9 5362440
40
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
41
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
42
Mycophenolic acid Approved Phase 2 24280-93-1 446541
43
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
44
Fludarabine Approved Phase 2,Phase 1 75607-67-9, 21679-14-1 30751
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
47
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2 24356-66-9 21704 32326
48
Aldesleukin Approved Phase 1, Phase 2,Phase 2 85898-30-2, 110942-02-4
49
Fondaparinux Approved, Investigational Phase 2 104993-28-4
50
Durvalumab Approved, Investigational Phase 2,Phase 1 1428935-60-7

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
2 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
3 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
4 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ (V503-006) Completed NCT01047345 Phase 3
5 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
6 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed NCT03158220 Phase 3
7 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
8 GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
9 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
10 Safety and Immunogenicity Study of V503 (GARDASILâ„¢9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Completed NCT01376349 Phase 3 prasterone
13 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Active, not recruiting NCT01536392 Phase 3 Granisetron;Ondansetron
14 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Active, not recruiting NCT00943722 Phase 3
15 Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer Unknown status NCT01097239 Phase 1, Phase 2
16 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
17 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Completed NCT00941070 Phase 2 triapine;cisplatin
19 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
20 Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
22 Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2) Completed NCT00188578 Phase 1, Phase 2
23 Effectiveness of an Individualized Symptom Education Program (ISEP) Completed NCT00275353 Phase 2
24 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
25 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
26 A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Completed NCT00551187 Phase 2
27 Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
28 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
29 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
30 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
31 Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 2 Cisplatin;Triapine
32 Image-Guided Gynecologic Brachytherapy Recruiting NCT02993900 Phase 2
33 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers Recruiting NCT03439085 Phase 2
34 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
35 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
36 Image-Guided Gynecologic Brachytherapy Active, not recruiting NCT01399658 Phase 2
37 Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
38 Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) Withdrawn NCT00365443 Phase 2
39 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
40 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
41 Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis Completed NCT00002949 Phase 1 paclitaxel;vinorelbine tartrate
42 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery Completed NCT00842452 Phase 1 topotecan hydrochloride
43 Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
44 Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) Completed NCT00851643 Phase 1
45 Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies Completed NCT00335998 Phase 1 triapine;cisplatin
46 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
47 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
48 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
49 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
50 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Sources

Genetic Tests for Vaginal Cancer

About this section
Sources

Anatomical Context for Vaginal Cancer

About this section

MalaCards organs/tissues related to Vaginal Cancer:

42
Testes, Cervix, Uterus, Brain, T Cells, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Cancer:

20
The Vagina
Sources

Publications for Vaginal Cancer

About this section

Articles related to Vaginal Cancer:

(show top 50) (show all 144)
# Title Authors Year
1
Importance of Colposcopy Impression in the Early Diagnosis of Posthysterectomy Vaginal Cancer. ( 30418351 )
2019
2
Total Colpectomy Increases the Risk of Postoperative Hydronephrosis in Vaginal Cancer Patients. ( 29469636 )
2018
3
Laterally extended endopelvic resection with nephrectomy for vaginal cancer. ( 30454878 )
2018
4
Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. ( 30516621 )
2018
5
Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. ( 29159773 )
2017
6
Abdominal radical trachelectomy for vaginal cancer - A case report. ( 28664182 )
2017
7
Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint. ( 28796063 )
2017
8
Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group. ( 29086206 )
2017
9
MR Imaging of Vulvar andA Vaginal Cancer. ( 28668156 )
2017
10
Sentinel lymph node mapping with indocyanine green in vaginal cancer. ( 28541627 )
2017
11
Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. ( 27486283 )
2016
12
Radical Hysterectomy and Total Abdominal Vaginectomy for Primary Vaginal Cancer. ( 26825828 )
2016
13
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. ( 26790773 )
2016
14
Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). ( 26768782 )
2016
15
Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. ( 26914159 )
2016
16
Brachytherapy improves survival in primary vaginal cancer. ( 27036631 )
2016
17
Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. ( 27327154 )
2016
18
Breast metastasis from vaginal cancer. ( 27444140 )
2016
19
Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. ( 26970567 )
2016
20
High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). ( 27010135 )
2016
21
Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. ( 27536721 )
2016
22
Outcomes with image-based interstitial brachytherapy for vaginal cancer. ( 27321150 )
2016
23
Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute. ( 27430086 )
2016
24
Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. ( 30814173 )
2016
25
Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer. ( 26461231 )
2015
26
Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate. ( 25614068 )
2015
27
Sarcoid-like reaction mimicking vaginal cancer recurrence. ( 26420533 )
2015
28
Management of Vaginal Cancer. ( 26411952 )
2015
29
Patterns of care and brachytherapy boost utilization for vaginal cancer in the United States. ( 25413431 )
2015
30
Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. ( 25966291 )
2015
31
Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. ( 25456026 )
2015
32
Vulval and vaginal cancer in pregnancy. ( 26526939 )
2015
33
LASER VAPORIZATION IN VULVAR INTRAEPITHELIAL NEOPLASIA (VIN), VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN) AND CONDYLOMATA ACUMINATA: IGCS-0093 Vulvar and Vaginal Cancer. ( 25955950 )
2015
34
PROGNOSTIC SIGNIFICANCE OF TUMOR SIZE IN SQUAMOUS CELL CARCINOMA OF THE VULVA: IGCS-0107 Vulvar and Vaginal Cancer. ( 25955951 )
2015
35
Staging for vaginal cancer. ( 25847318 )
2015
36
Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. ( 24505474 )
2014
37
Successful pregnancy after uterus-sparing chemoradiation therapy for vaginal cancer. ( 25432539 )
2014
38
HDR brachytherapy for the reirradiation of cervical and vaginal cancer: Analysis of efficacy and dosage delivered to organs at risk. ( 24161366 )
2014
39
Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer. ( 25254565 )
2014
40
Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. ( 24785610 )
2014
41
Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. ( 24423603 )
2014
42
Vaginal cancer in a patient with complicated prolapse history: a case report. ( 25181382 )
2014
43
Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: A National Cancer Data Base (NCDB) study. ( 25281493 )
2014
44
Uterine prolapse complicated by vaginal cancer: a case report and literature review. ( 24481208 )
2014
45
Acr appropriateness Criteria management of vaginal cancer. ( 24575547 )
2013
46
A case of vaginal cancer with uterine prolapse. ( 25371880 )
2013
47
Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? ( 23212765 )
2013
48
Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy. ( 24080298 )
2013
49
Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer. ( 23453679 )
2013
50
Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. ( 24396823 )
2013
Sources

Variations for Vaginal Cancer

About this section

Cosmic variations for Vaginal Cancer:

9 (show top 50) (show all 201)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6917051 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 0
2 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 0
3 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
4 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 17:7673814-7673814 0
5 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 0
6 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 0
7 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 0
8 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 0
9 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
10 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 17:7675185-7675185 0
11 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 17:7673745-7673745 0
12 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
13 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 0
14 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 17:7673802-7673802 0
15 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 17:7673790-7673790 0
16 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 0
17 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 17:7676068-7676068 0
18 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 0
19 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 17:7674237-7674237 0
20 COSM6917055 TOP1 cervix,NS,carcinoma,squamous cell carcinoma c.1897C>T p.Q633* 20:41118243-41118243 0
21 COSM6933657 TGFBR2 cervix,NS,carcinoma,squamous cell carcinoma c.931G>T p.E311* 3:30672114-30672114 0
22 COSM6918339 TET2 cervix,NS,carcinoma,squamous cell carcinoma c.2659G>A p.E887K 4:105236601-105236601 0
23 COSM6906292 TENT5C cervix,NS,carcinoma,squamous cell carcinoma c.722G>T p.G241V 1:117623590-117623590 0
24 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 19:1220630-1220630 0
25 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 19:1220505-1220505 0
26 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 19:1207082-1207082 0
27 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 19:1218446-1218446 0
28 COSM6933523 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 0
29 COSM6977087 SPOP cervix,NS,carcinoma,squamous cell carcinoma c.962C>T p.A321V 17:49601883-49601883 0
30 COSM421102 ROS1 cervix,NS,carcinoma,squamous cell carcinoma c.1682C>T p.P561L 6:117389427-117389427 0
31 COSM6977085 RB1 cervix,NS,carcinoma,squamous cell carcinoma c.1630A>T p.R544* 13:48381378-48381378 0
32 COSM6910533 RAD54L cervix,NS,carcinoma,squamous cell carcinoma c.1900C>T p.R634C 1:46277847-46277847 0
33 COSM6977079 RAD50 cervix,NS,carcinoma,squamous cell carcinoma c.432G>C p.E144D 5:132587654-132587654 0
34 COSM6977082 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1702C>T p.Q568* 8:116848948-116848948 0
35 COSM6977083 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1681C>T p.Q561* 8:116848969-116848969 0
36 COSM6968882 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3418G>A p.E1140K 20:42106824-42106824 0
37 COSM6975050 PTPRS cervix,NS,carcinoma,squamous cell carcinoma c.5630C>G p.S1877C 19:5208249-5208249 0
38 COSM6917045 PTPRD cervix,NS,carcinoma,squamous cell carcinoma c.1693G>A p.E565K 9:8504390-8504390 0
39 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 10:87952142-87952142 0
40 COSM5945791 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.65A>G p.D22G 10:87864534-87864534 0
41 COSM4822061 POLE cervix,NS,carcinoma,squamous cell carcinoma c.865G>A p.E289K 12:132676590-132676590 0
42 COSM6937072 PIK3R1 cervix,NS,carcinoma,squamous cell carcinoma c.1859A>G p.D620G 5:68296215-68296215 0
43 COSM43062 PIK3CG cervix,NS,carcinoma,squamous cell carcinoma c.53G>A p.R18Q 7:106867614-106867614 0
44 COSM5878662 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1579G>A p.D527N 3:179218249-179218249 0
45 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 3:179234286-179234286 0
46 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 0
47 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 3:179218294-179218294 0
48 COSM12584 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1357G>A p.E453K 3:179210291-179210291 0
49 COSM7351397 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.2924G>A p.R975K 3:179230364-179230364 0
50 COSM27134 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3130A>G p.N1044D 3:179234287-179234287 0
Sources

Expression for Vaginal Cancer

About this section
Search GEO for disease gene expression data for Vaginal Cancer.
Sources

Pathways for Vaginal Cancer

About this section

Pathways related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Antigen Presentation- Folding, assembly and peptide loading of class I MHC 67
10.02 HLA-G SAR1B
Sources

GO Terms for Vaginal Cancer

About this section

Cellular components related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 8.62 HLA-G SAR1B

Biological processes related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 8.62 HLA-G SAR1B
Sources

Sources for Vaginal Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....